Form 4: OrbiMed Advisors Sells Passage Bio Shares in Multiple Transactions

OrbiMed Advisors LLC, a significant shareholder in Passage Bio, Inc., has sold a total of 97,103 shares of common stock in two separate transactions.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP VII LLC, reported the sale of Passage Bio, Inc. common stock.
• On December 4, 2024, 76,200 shares were sold at a weighted average price of $0.79 per share, with prices ranging from $0.75 to $0.82.
• On December 6, 2024, an additional 20,903 shares were sold at a weighted average price of $0.82 per share, with prices ranging from $0.81 to $0.83.
• Following these transactions, OrbiMed's beneficial ownership decreased to 7,697,466 shares.
• The shares are held by OrbiMed Private Investments VII, LP, with OrbiMed Capital GP VII LLC as the general partner and OrbiMed Advisors LLC as the managing member.

Sentiment

Score: 4

Explanation: The document indicates a reduction in holdings by a major shareholder, which is generally viewed negatively by the market. However, it is a routine transaction and not necessarily indicative of a major issue.

Negatives

• OrbiMed Advisors, a significant shareholder, has reduced its stake in Passage Bio through these sales.

Risks

• Continued selling pressure from major shareholders like OrbiMed could negatively impact the stock price.
• The weighted average sale prices indicate potential price volatility in the stock.

Industry Context

This transaction is a routine disclosure of share sales by a major shareholder and does not necessarily indicate a change in the company's prospects or performance. It is common for investment firms to adjust their holdings.

Comparison to Industry Standards

• Share sales by institutional investors are a common occurrence in the biotech industry.
• Similar transactions are regularly reported by other investment firms holding positions in publicly traded biotech companies.
• The size of the sale is not unusual for a firm with a significant stake like OrbiMed.

Stakeholder Impact

• The share sales could potentially put downward pressure on the stock price, impacting shareholders.
• The transactions may not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

OrbiMed Advisors, Passage Bio, Share Sale, Beneficial Ownership, Stock Transaction, SEC Form 4